F. Dentali, N. Riva, M. Crowther, A. G. Turpie, G. Y. Lip et al., Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature, Circulation, vol.126, pp.2381-91, 2012.

C. T. Ruff, R. P. Giugliano, and E. Braunwald, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials, Lancet, vol.383, pp.955-62, 2014.

C. Aj, P. Amarenco, and S. Haas, Xantus: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation, Eur Heart J, vol.37, pp.1145-53, 2016.

M. H. Prins, A. Lensing, and R. Bauersachs, EINSTEIN investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized analysis, Thromb J, vol.11, p.21, 2013.

J. W. Cheng and G. Barillari, Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions, J Clin Pharm Ther, vol.39, pp.118-153, 2014.

C. Chai-adisaksopha, M. Crowther, T. Isayama, and W. Lim, The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis, Blood, vol.124, pp.2450-2458, 2014.

, Les anticoagulants en France en 2014 : états des lieux, synthèse et surveillance, Agence Nationale de sécurité du médicament et des produits de santé (ANSM), 2014.

R. Forster and M. Stewart, Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair, Cochrane Database Syst rev, vol.30, p.3, 2016.

H. Heidbuchel, P. Verhamme, and M. Alings, Updated European Heart Rhythm Association (EHRA) practical guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation, Europace, vol.17, pp.1467-507, 2015.

S. J. Connolly, M. D. Ezekowitz, and S. Yusuf, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, and J. Garg, Rivaroxaban versus warfarin in non-valvular atrial fibrillation, ROCKET AF Investigators, vol.365, pp.883-91, 2011.

C. B. Granger, J. H. Alexander, and J. J. Mcmurray, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, pp.981-92, 2011.

R. P. Guigliano, C. T. Ruff, and E. Braunwald, Edoxaban versus warfarin in patients with atrial fibrillation, ENGAGE. N Engl J Med, vol.369, pp.2093-104, 2013.

S. V. Konstantinides, A. Torbicki, and G. Agnelli, ESC Guidelines on the diagnosis and management of acute pulmonary embolism, Eur Heart J, vol.35, pp.3033-69, 2014.

S. Schulman, C. Kearon, and A. K. Kakkar, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, vol.361, pp.2342-52, 2009.
URL : https://hal.archives-ouvertes.fr/ujm-00439704

S. Laporte, P. Mismetti, and H. Décousus, Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry, Circulation, vol.117, pp.1711-1717, 2008.
URL : https://hal.archives-ouvertes.fr/ujm-00439761

J. L. Weitz, M. H. Lensing, and R. Prins, Rivaroxaban or aspirin for extended treatment of venous thromboembolism, N Engl J Med, vol.376, pp.1211-1233, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02051875

D. Caldeira, F. B. Rodrigues, and M. Barra, Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis, Heart, vol.101, pp.1204-1215, 2015.

C. Chai-adisaksopha, C. Hillis, W. Lim, K. Boonyawat, K. Moffat et al., Hemodialysis for the treatment of dabigatran-associated bleeding : a case report and systematic review, J Thromb Haemost, vol.13, pp.1790-1798, 2015.

D. A. Parasrampuria, T. Marbury, N. Matsushima, S. Chen, and P. K. Wickremasingha, He L. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis, Thromb Haemost, vol.113, pp.719-727, 2015.

X. Wang, S. Mondal, J. Wang, G. Tirucherai, D. Zhang et al., Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects, Am J Cardiovasc Drugs, vol.14, pp.147-154, 2014.

E. Ollier, S. Hodin, J. Lanoiselée, J. Escal, S. Accassat et al., Effect of activated charcoal on rivaroxaban complex absorption, Clin Pharmacokinet, vol.56, pp.793-801, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01424733

J. Steffel, P. Verhamme, T. S. Potpara, P. Albaladejo, M. Antz et al., European Heart Rythm Association practical guide on the use of the non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, vol.39, pp.1330-1393, 2018.

S. Schulman, P. L. Gross, B. Ritchie, S. Nahirniak, Y. Lin et al., Prothrombin complex concentrate for major bleeding on factor Xa inhibitors : a prospective cohort study, Thromb Haemost, vol.118, pp.842-851, 2018.

A. Majeed, A. Agren, M. Holmstrom, M. Bruzelius, R. Chaireti et al., Management of rivaroxaban-or apixaban-associated major bleeding with prothrombin complex concentrates : a cohort study, Blood, vol.130, pp.1706-1712, 2017.

E. Perzborn, A. Gruber, H. Tinel, U. M. Marzec, U. Buetehorn et al., Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates, Thromb Haemost, vol.110, pp.162-172, 2013.

L. M. Harinstein, J. W. Morgan, and N. Russo, Treatment of dabigatran-associated bleeding: case report and review of the literature, J Pharm Pract, vol.26, pp.264-269, 2013.

L. Ivanciu, R. Toso, P. Margaritis, G. Pavani, H. Kim et al., A zymogenlike factor Xa variant corrects the coagulation defect in hemophilia, Nat Biotechnol, vol.29, pp.1028-1033, 2011.

N. Thalji, L. Ivanciu, R. Davidson, P. Gimotty, S. Krishnaswamy et al., A rapid pro-hemostatic approach to overcome direct oral anticoagulants, Nat Med, vol.22, pp.924-932, 2016.

D. Parsons-rich, F. Hua, G. Li, C. Kantaridis, D. Pittman et al., Phase 1 doseescalating study to evaluate the safety, pharmacokinetics, and pharmacodynamcs of a recombinant factor Xa variant (FXa), J Thromb Haemost, vol.15, pp.931-937, 2017.

D. Verhoef, K. M. Visscher, C. R. Vosmeer, K. L. Cheung, P. Reitsma et al., Engineered factor Xa variants retain procagulant activity independent of direct factor Xa inhibitors, Nat Commun, vol.8, pp.528-538, 2017.

A. C. Von-drygalski, V. Bhat, J. H. Griffin, A. J. Gale, and L. O. Mosnier, Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant, J Thromb Haemost, vol.12, pp.363-372, 2014.

C. Ruff, R. Giugliano, and E. Antman, Management of bleeding with non-vitamin K antagonists oral anticoagulants in the era of specific reversal agents, Circulation, vol.134, pp.248-261, 2016.

A. J. Bakhru, S. Laulicht, B. Steiner, S. Grosso, M. Brown et al., Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban, Thromb Haemost, vol.117, pp.238-245, 2017.

D. Stephan, E. M. Cordeanu, A. Faller, C. Mirea, V. Schini-kerth et al., Les anticoagulants oraux directs, pharmacologie et principales indications, vol.23, pp.356-65, 2017.

F. Schiele, J. Van-ryn, K. Canada, C. Newsome, E. Sepulveda et al., A specific antidote for dabigatran : functional and structural characterisation, Blood, vol.121, pp.3554-3562, 2013.

C. V. Pollack, P. A. Reilly, J. Van-ryn, J. Eikelboom, S. Glund et al., Idarucizumab for dabigatran reversal -full cohort analysis, N Engl J Med, vol.377, pp.431-441, 2017.

N. Gendron, J. Gay, M. Lemoine, P. Gaussem, . Lillo-le et al., Usefulness of initial plasma dabigatran concentration to predict rebound after reversal, Heamatologica, vol.103, pp.226-229, 2018.

M. Schmol, S. Glund, A. Harada, S. Imazu, D. Smet et al., Idarucizumab does not have procoagulant effects : assessment of thrombosis biomarkers in healthy volunteers, Thromb Haemost, vol.117, pp.269-276, 2017.

A. Trinh-duc, . Lillo-le, A. Louet, E. Tellier, T. Viard et al., Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database, Thromb Res, vol.146, pp.43-45, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02044161

G. Lu, F. R. Deguzman, S. J. Hollenbach, M. J. Karbarz, K. Abe et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat Med, vol.19, pp.446-451, 2013.

S. Connolly, T. Milling, J. Eikelboom, M. Gibson, J. Curnutte et al., Andexanet alfa for acute major bleeding associated with factor Xa inhibitors, N Engl J Med, vol.375, pp.1131-1141, 2016.

D. M. Siegal, J. T. Curnutte, S. J. Connolly, G. Lu, P. Conley et al., Andexanet alfa for the reversal of factor Xa inhibitor activity, N Engl J Med, vol.373, pp.2413-2424, 2015.

T. Myles, F. C. Church, H. C. Whinna, D. Monard, and S. R. Stone, Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes, J Biol Chem, vol.273, pp.31203-31208, 1998.

W. P. Sheffield, M. D. Lambourne, L. J. Eltringham-smith, V. Bhakta, D. M. Arnold et al., A. gammaT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo, J Thromb Haemost, vol.12, pp.1110-1115, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02073505

G. Jourdi, I. Gouin-thibault, V. Siguret, S. Gandrille, P. Gaussem et al., GammaT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo, Thromb Haemost, 2018.

A. L. Dans, S. J. Connolly, L. Wallentin, S. Yang, J. Nakamya et al., Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, Circulation, vol.127, pp.634-674, 2013.

C. Anaïs and ;. Id, Étude observationnelle et descriptive des complications hémorragiques sous anticoagulants oraux chez les patients atteints de fibrillation auriculaire non valvulaire au SAU Bel Air du CHR Metz-Thionville entre septembre 2013 et septembre, p.1733606, 2014.

D. Poli, E. Antonucci, and S. Testa, Bleeding risk in very old patients on Vitamin K antagonist treatment results of a prospective collaborative study on elderly patients followed by Italian centres for anticoagulation, Circulation, vol.124, issue.7, pp.824-829, 2011.

I. L. Holster, V. E. Valkhoff, and E. J. Kuipers, New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis, Gastroenterology, vol.145, issue.1, pp.105-112, 2013.

B. J. Connolly, L. A. Pearce, and R. G. Hart, Vitamin K Antagonists and Risk of Subdural Hematoma Meta-Analysis of Randomized Clinical Trials, Stroke, issue.6, pp.1672-1678, 2014.

J. Peeterbroeck, C. Danguy, C. Lelubre, M. Meulemans, and S. Higuet, Hémorragies sous anticoagulants oraux en gériatrie : résultats d'une étude observationnelle, Geriatr Psychol Neuropsychiatr Vieil, vol.14, issue.4, pp.406-418, 2016.

T. I. Shireman, P. A. Howard, T. F. Kresowik, and E. F. Ellerbeck, Combined anticoagulantantiplatelet use and major bleeding events in elderly atrial fibrillation patients, Stroke, vol.35, pp.2362-2369, 2004.

M. Sholzberg, K. Pavenski, N. Shehata, C. Cserti-gazdewich, and Y. Lin, Bleeding complications from the direct oral anticoagulants, BMC Hematol, vol.15, p.18, 2015.

G. Palareti, J. Hirsh, C. Legnani, C. Manotti, D. Angelo et al., Oral anticoagulation treatment in the elderly : a nested, prospective, case-control study, Arch Intern Med, vol.160, pp.470-478, 2000.

G. Ocak, C. Y. Vossen, and W. Lijfering, Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function, Circulation, vol.129, pp.683-691, 2014.

J. B. Olesen, G. Y. Lip, and A. Kamper, Stroke and bleeding in atrial fibrillation with chronic kidney disease, N Engl J Med, vol.367, pp.625-635, 2012.

B. Böttger, M. Wehling, and R. M. Bauersachs, Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: a retrospective analysis based on 6,725 VTE patients, Thromb Res, vol.134, pp.1014-1019, 2014.

S. V. Brodsky, T. Nadasdy, and B. H. Rovin, Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate, Kidney Int, vol.80, pp.181-189, 2011.

N. A. Limdi, T. M. Beasley, and M. F. Baird, Kidney function influences warfarin responsiveness and hemorrhagic complications, J Am Soc Nephrol, vol.20, pp.912-921, 2009.

J. Kooiman, N. Van-rein, and B. Spaans, Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease, PLoS One, vol.9, p.94420, 2014.

R. G. Kalaitzidis, A. Duni, and G. Liapis, Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity, Int Urol Nephrol, vol.49, pp.1401-1407, 2017.

M. Ryan, K. Ware, and Z. Qamri, Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats, Nephrol Dial Transplant, vol.29, pp.2228-2234, 2014.

S. T. Shafi, H. Negrete, and P. Roy, A case of dabigatran-associated acute renal failure, Wis Med J, vol.112, pp.173-175, 2013.

J. Wendte, G. Voss, and B. Vanoverschelde, Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury, Am J Health Syst Pharm, vol.73, pp.563-567, 2016.

Y. Chan, Y. Yeh, and L. See, Acute kidney injury in asians with atrial fibrillation treated with dabigatran or warfarin, J Am Coll Cardiol, vol.68, pp.2272-2283, 2016.

R. M. Bauersachs, Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups, Eur J Intern Med, vol.25, pp.600-606, 2014.

H. Heidbuchel, P. Verhamme, and M. Alings, Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation, Europace, vol.17, pp.1467-1507, 2015.

J. Harenberg, Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes, J Thromb Haemost, vol.2, pp.547-550, 2004.

A. Levin, M. Ben-artzi, and P. Beckerman, Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study, Drugs Aging, vol.26, pp.77-85, 2009.

A. C. Milne, A. Avenell, and J. Potter, Meta-analysis: protein and energy supplementation in older people, Ann Intern Med, vol.144, pp.37-48, 2006.

E. R. Mcgrath, A. S. Go, and Y. Chang, Use of oral anticoagulant therapy in older adults with atrial fibrillation after acute ischemic stroke, J Am Geriatr Soc, vol.65, pp.241-248, 2017.

J. Donzé, C. Clair, and B. Hug, Risk of falls and major bleeds in patients on oral anticoagulation therapy, Am J Med, vol.125, pp.773-778, 2012.

P. Kirchhof, S. Benussi, and D. Kotecha, ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, pp.2893-2962, 2016.

H. Autorité-de-santé, Evaluation and management of elderly patients at risk of falls, 2009.

, American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults, J Am Geriatr Soc, vol.63, pp.2227-2246, 2015.

L. G. Jacobs, H. H. Billett, and K. Freeman, Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study, Am J Geriatr Pharmacother, vol.7, pp.159-166, 2009.

G. C. Flaker, J. Pogue, and S. Yusuf, Cognitive function and anticoagulation control in patients with atrial fibrillation, Circ Cardiovasc Qual Outcomes, vol.3, pp.277-283, 2010.

S. Armand-branger, Le vieillissement de la population française et ses conséquences, J Pharm Clin, vol.30, pp.159-166, 2011.

J. De-rotrou, L. Battal-merlet, and E. Wenisch, Relevance of 10-min delayed recall in dementia screening, Eur J Neurol, vol.14, pp.144-149, 2007.

C. M. Seux, V. Pauly, and V. , Adverse drug events in hospitalized elderly patients in a geriatric medicine unit: study of prevalence and risk factors, Rev Med Interne, vol.30, pp.393-400, 2009.

G. H. Lyman, Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis, Cancer, vol.117, pp.1334-1349, 2011.

J. Khalil, B. Bensaid, and H. Elkacemi, Venous thromboembolism in cancer patients: an underestimated major health problem, World J Surg Oncol, vol.13, p.204, 2015.

D. Farge, J. Trujillo-santos, and P. Debourdeau, Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism, Medicine (Baltimore), vol.94, p.1235, 2015.

H. T. Sørensen, L. Mellemkjaer, and J. Olsen, Prognosis of cancers associated with venous thromboembolism, N Engl J Med, vol.343, pp.1846-1850, 2000.

C. E. Chee, A. A. Ashrani, and R. S. Marks, Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study, Blood, vol.123, pp.3972-3978, 2014.

R. D. Hull, G. F. Pineo, and R. F. Brant, Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms, Am J Med, vol.120, pp.72-82, 2007.

G. H. Lyman, K. Bohlke, and A. A. Khorana, Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update, J Clin Oncol, vol.33, pp.654-656, 2014.

S. Schulman, C. Kearon, A. K. Kakkar, S. Schulman, A. K. Kakkar et al., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, N Engl J Med, vol.361, pp.764-772, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01030866